The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer

Biochemistry and Cell Biology

Volumn 90, Issue 1, 2012, Pages 96-107

  Greenaway, James B ^a,b   Koehler, Anne ^b   McCulloch, Christopher A ^b   Petrik, James ^c   Brown, Theodore J ^a   Ringuette, Maurice J ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

Epithelial ovarian cancer; Mouse model; SPARC

Indexed keywords

ANTITUMOR EFFECT; COLLAGEN CONTENT; COLLAGEN FIBRILS; DISEASE PROGRESSION; INTRAPERITONEAL; MICROENVIRONMENTS; MOUSE MODELS; ORTHOTOPIC; OVARIAN CANCERS; OVARIAN TUMOR; SPARC; TUMOR CELLS; WILD TYPES;

CELLS; COLLAGEN; CYTOLOGY; DISEASES; TUMORS;

MAMMALS;

COLLAGEN FIBRIL; OSTEONECTIN;

ABDOMINAL WALL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; WILD TYPE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; OSTEONECTIN; OVARIAN NEOPLASMS; TUMOR MICROENVIRONMENT;

MUS;

EID: 84862838710     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/o11-047     Document Type: Article

References (35)

1. Barth P.J. Moll R. Ramaswamy A. 2005. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Arch. 446 (5): 532-536. 10.1007/s00428-005- 1256-9 15838642
2. Beck A.H. Espinosa I. Gilks C.B. Van De Rijn M. West R.B. 2008. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab. Invest, 88 (6): 591-601. 10.1038/labinvest.2008.31 18414401
3. Bergamaschi A. Tagliabue E. Sorlie T. Naume B. Triulzi T. Orlandi R. et al. 2008. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 214 (3): 357-367. 10.1002/path.2278 18044827
4. Bradshaw A.D. Graves D.C. Motamed K. Sage E.H. 2003. SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proc. Natl. Acad. Sci. U.S.A. 100 (10): 6045-6050. 10.1073/pnas. 1030790100 12721366
5. Bradshaw A.D. Baicu C.F. Rentz T.J. Van Laer A.O. Bonnema D.D. Zile M.R. 2010. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am. J. Physiol. Heart Circ. Physiol. 298 (2): H614-H622. 10.1152/ajpheart.00474.2009 20008277
6. Brown T.J. Shaw P.A. Karp X. Huynh M.H. Begley H. Ringuette M.J. 1999. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol. Oncol. 75 (1): 25-33. 10.1006/gyno.1999.5552 10502421
7. Bull Phelps S.L. Carbon J. Miller A. Castro-Rivera E. Arnold S. Brekken R.A. Lea J.S. 2009. Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am. J. Obstet. Gynecol. 200 (2): 180.e1-180.e7. 10.1016/j.ajog.2008.08.047 18992864
8. Chlenski A. Cohn S.L. 2010. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin. Cell Dev. Biol. 21 (1): 55-65. 10.1016/j.semcdb.2009.11.018 19958839
9. Coleman R. 2011. Picrosirius red staining revisited. Acta Histochem. 113 (3): 231-233. 10.1016/j.acthis.2010.02.002 20188402
10. Cui L. Johkura K. Liang Y. Teng R. Ogiwara N. Okouchi Y. et al. 2002. Biodefense function of omental milky spots through cell adhesion molecules and leukocyte proliferation. Cell Tissue Res. 310 (3): 321-330. 10.1007/s00441-002- 0636-6 12457231
11. Egeblad M. Rasch M.G. Weaver V.M. 2010. Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 22 (5): 697-706. 10.1016/j.ceb.2010.08.015 20822891
12. Freedman R.S. Deavers M. Liu J. Wang E. 2004. Peritoneal inflammation ' a microenvironment for epithelial ovarian cancer (EOC). J. Transl. Med. 2 (1): 23-33. 10.1186/1479-5876-2-23 15219235
13. Greenaway J. Moorehead R. Shaw P. Petrik J. 2008. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol. Oncol. 108 (2): 385-394. 10.1016/j.ygyno.2007.10.035 18036641
14. Jager K.J. Van Dijk P.C. Zoccali C. Dekker F.W. 2008. The analysis of survival data: the Kaplan-Meier method. Kidney Int. 74 (5): 560-565. 10.1038/ki.2008.217 18596735
15. Jemal A. Siegel R. Xu J. Ward E. 2010. Cancer statistics, 2010. CA Cancer J. Clin. 60 (5): 277-300. 10.3322/caac.20073 20610543
16. Khan S.M. Funk H.M. Thiolloy S. Lotan T.L. Hickson J. Prins G.S. et al. 2010. In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin. Exp. Metastasis, 27 (3): 185-196. 10.1007/s10585-010-9317-0 20229256
17. Kupprion C. Motamed K. Sage E.H. 1998. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 273 (45): 29635-29640. 10.1074/jbc.273.45.29635 9792673
18. Lehmann S. O'Kelly J. Raynaud S. Funk S.E. Sage E.H. Koeffler H.P. 2007. Common deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC-null mice. Leukemia, 21 (9): 1931-1936. 10.1038/sj.leu.2404852 17625608
19. Mok S.C. Chan W.Y. Wong K.K. Muto M.G. Berkowitz R.S. 1996. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene, 12 (9): 1895-1901. 8649850
20. Nachman R.L. Rafii S. 2008. Platelets, petechiae, and preservation of the vascular wall. N. Engl. J. Med. 359 (12): 1261-1270. 10.1056/NEJMra0800887 18799560
21. Nie J. Sage E.H. 2009. SPARC functions as an inhibitor of adipogenesis. Journal of Cell Commun. Signal. 3 (3-4): 247-254. 10.1007/s12079-009-0064-4 19798596
22. Paley P.J. Goff B.A. Gown A.M. Greer B.E. Sage E.H. 2000. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol. Oncol. 78 (3): 336-341. 10.1006/gyno.2000.5894 10985890
23. Pickering J.G. Boughner D.R. 1991. Quantitative assessment of the age of fibrotic lesions using polarized light microscopy and digital image analysis. Am. J. Pathol. 138 (5): 1225-1231. 2024708
24. Rentz T.J. Poobalarahi F. Bornstein P. Sage E.H. Bradshaw A.D. 2007. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J. Biol. Chem. 282 (30): 22062-22071. 10.1074/jbc.M700167200 17522057
25. Sahagun G. Moore S.A. Fabry Z. Schelper R.L. Hart M.N. 1989. Purification of murine endothelial cell cultures by flow cytometry using fluorescein-labeled griffonia simplicifolia agglutinin. Am. J. Pathol. 134 (6): 1227-1232. 2757116
26. Said N. Motamed K. 2005. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am. J. Pathol. 167 (6): 1739-1752. 10.1016/S0002-9440(10)61255-2 16314484
27. Said N. Najwer I. Motamed K. 2007 a. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am. J. Pathol. 170 (3): 1054-1063. 10.2353/ajpath.2007.060903 17322388
28. Said N.A. Najwer I. Socha M.J. Fulton D.J. Mok S.C. Motamed K. 2007 b. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia, 9 (1): 23-35. 10.1593/neo.06658 17325741
29. Said N.A. Elmarakby A.A. Imig J.D. Fulton D.J. Motamed K. 2008. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia, 10 (10): 1092-1104. 18813349
30. Schwarzbauer J.E. 1991. Identification of the fibronectin sequences required for assembly of a fibrillar matrix. J. Cell Biol. 113 (6): 1463-1473. 10.1083/jcb.113.6.1463 2045422
31. Socha M.J. Said N. Dai Y. Kwong J. Ramalingam P. Trieu V. et al. 2009. Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia, 11 (2): 126-135. 19177197
32. Song G. Cai Q.F. Mao Y.B. Ming Y.L. Bao S.D. Ouyang G.L. 2008. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1α expression through the PI3-K/Akt pathway. Cancer Sci. 99 (10): 1901-1907. 19016748
33. Wei W. Kong B. Yang Q. Qu X. 2010. Hepatocyte growth factor enhances ovarian cancer cell invasion through downregulation of thrombospondin-1. Cancer Biol. Ther. 9 (2): 79-87. 10.4161/cbt.9.2.10280 19959938
34. Weis S.M. Cheresh D.A. 2005. Pathophysiological consequences of VEGF-induced vascular permeability. Nature, 437 (7058): 497-504. 10.1038/nature03987 16177780
35. Yiu G.K. Chan W.Y. Ng S.W. Chan P.S. Cheung K.K. Berkowitz R.S. Mok S.C. 2001. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 159 (2): 609-622. 10.1016/S0002-9440(10) 61732-4 11485919